Nature selects the most promising trials for this 2023

Now that the coronavirus pandemic has given a bit of a truce and scientific research is once again analyzing other pathologies, in nature medicine have brought together 11 researchers from different areas of Medicine so that the main trials that are being developed and that will bear fruit throughout this new year that is beginning can be counted.

ANDCancer once again occupies a significant part of these advances, but new medicines for diseases such as Parkinson’s or Alzheimer’s are also presented. Among these researchers is the Spanish Jordi Salas Salvadó, What does the Mediterranean diet do for weight loss?

Mediterranean diet

The Spanish Jordi Salas Salvadó argues that an intensive lifestyle intervention program based on traditional Mediterranean diet “is a long-term sustainable approach to achieving weight loss in obese and overweight adults. These changes, he defends, will have a beneficial effect on cardiovascular health.

Advances in tumors

The scientific director of US Oncology Research, Robert L Colemanhighlights that the next “most imminent and important” trial result expected is on mirvetuximab soravtansine for the treatment of ovarian cancer. Despite the fact that it obtained accelerated approval from the Food and Drug Administration (FDA), a trial must be carried out to confirm its safety and efficacy, the results of which will not be long in coming.

Nicola AcetoAssociate Professor of Molecular Oncology at ETH Zurich, investigate metastasis and explains that the most recent research reveals that these are driven “mainly by groups of circulating tumor cells (CTC).” There are drugs, he states, such as digoxin, that can dissociate these cells. Currently, they have established a phase 1 trial in which they will examine the blood of patients with advanced metastatic breast cancer and, in those cases that find CTC, this drug will be administered for three weeks.

Although not all cancer trials deal with treatments, but also with improving diagnosis. Anssi AuvinenProfessor of Health Sciences at the University of Tampere, in Finland, comments that they have set themselves the goal detect only “clinically relevant” aggressive prostate cancer and minimize the diagnosis of low-risk, clinically insignificant cancers “that would constitute overdiagnosis.”

Vaccinated populations

Karen CanfellChair of the Australian Cancer Council Steering and Immunization Committee, explains that a trial has been launched internationally that will evaluate primary HPV screening in a heavily vaccinated population against this virus. With these immunizations, women are protected from cervical cancer.

The covid is still present, although with less danger, in the countries. It is because of that Glenda Graydirector of the South African Medical Research Council, details a trial, the results of which are expected in 2023, which aims to to evaluate the efficacy of Moderna’s vaccine against covid in adults infected with HIV to know how many doses are needed.

Advances in degenerative diseases

The expert simone spuler develops that patients muscular dystrophy they have stem cells that carry mutations and that prevents them from regenerating muscle. However, these mutations can be corrected and his group is working with these corrected cells to test their efficacy.

Roger Albinprofessor in the Department of Neurology at the University of Michigan, explains that the drug exetin is in phase 3 to treat Parkinson’s. It is a medication used for diabetes. “In this disease where there is no animal model for high predictive validity, this is probably the best there is,” he details. Even if the results were not positive, Albin says they will be just as important.

Olaf Valverdefocused on sleeping sickness caused by T. brucei rhodesiense, seeks to prove the efficacy of the drug fexinidazole against this pathology. This trial will compare its effectiveness with that of drugs such as melarsoprol, a derivative of arsenic “so toxic that it killed 5 percent of patients.”

Other major diseases that exist is the one studied by allan levey, professor at Emory University and director of the Alzheimer’s Disease Research Center at the same institution. By 2023, he hopes to have more data on lecanemaban investigational monoclonal antibody for the treatment of Alzheimer’s mild cognitive impairment. Good results have already been obtained through a large phase 3 confirmatory clinical trial that “show a significant reduction in clinical progression.”

The scientific director of the Institute of Gene Therapy San Raffaele Telethon (Italy), Luigi Naldinihowever, is waiting for the first data, in the long term, of the Gene editing strategies in sickle cell disease and thalassemia. In 2023, he hopes to see interim results from a trial where they are giving a single dose to patients with severe sickle cell disease, and they want to see if they have experienced a severe vaso-occlusive crisis for at least 12 consecutive months.

Although it may contain statements, data or notes from health institutions or professionals, the information contained in Redacción Médica is edited and prepared by journalists. We recommend to the reader that any health-related questions be consulted with a health professional.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button